- Home
- OPFI vs OCGN Comparison
OPFI vs OCGN Comparison
Compare OPFI & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- OCGN
- Stock Information
- Founded
- OPFI 2009
- OCGN 2013
- Country
- OPFI United States
- OCGN United States
- Employees
- OPFI N/A
- OCGN N/A
- Industry
- OPFI Finance: Consumer Services
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPFI Finance
- OCGN Health Care
- Exchange
- OPFI Nasdaq
- OCGN Nasdaq
- Market Cap
- OPFI 300.3M
- OCGN 283.3M
- IPO Year
- OPFI N/A
- OCGN N/A
- Fundamental
- Price
- OPFI $10.43
- OCGN $1.05
- Analyst Decision
- OPFI Buy
- OCGN Strong Buy
- Analyst Count
- OPFI 2
- OCGN 3
- Target Price
- OPFI $11.75
- OCGN $6.00
- AVG Volume (30 Days)
- OPFI 1.1M
- OCGN 2.7M
- Earning Date
- OPFI 08-06-2025
- OCGN 08-01-2025
- Dividend Yield
- OPFI 9.60%
- OCGN N/A
- EPS Growth
- OPFI N/A
- OCGN N/A
- EPS
- OPFI N/A
- OCGN N/A
- Revenue
- OPFI $320,831,000.00
- OCGN $4,754,000.00
- Revenue This Year
- OPFI $113.99
- OCGN N/A
- Revenue Next Year
- OPFI $9.05
- OCGN N/A
- P/E Ratio
- OPFI N/A
- OCGN N/A
- Revenue Growth
- OPFI 31.26
- OCGN N/A
- 52 Week Low
- OPFI $3.93
- OCGN $0.52
- 52 Week High
- OPFI $17.73
- OCGN $1.40
- Technical
- Relative Strength Index (RSI)
- OPFI 40.21
- OCGN 53.85
- Support Level
- OPFI $9.92
- OCGN $1.01
- Resistance Level
- OPFI $11.33
- OCGN $1.07
- Average True Range (ATR)
- OPFI 0.65
- OCGN 0.05
- MACD
- OPFI 0.06
- OCGN 0.00
- Stochastic Oscillator
- OPFI 26.69
- OCGN 66.48
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").